CA2264895C - Device and method for treating ophthalmic diseases - Google Patents

Device and method for treating ophthalmic diseases Download PDF

Info

Publication number
CA2264895C
CA2264895C CA002264895A CA2264895A CA2264895C CA 2264895 C CA2264895 C CA 2264895C CA 002264895 A CA002264895 A CA 002264895A CA 2264895 A CA2264895 A CA 2264895A CA 2264895 C CA2264895 C CA 2264895C
Authority
CA
Canada
Prior art keywords
capsule
biologically active
active molecule
eye
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002264895A
Other languages
English (en)
French (fr)
Other versions
CA2264895A1 (en
Inventor
Peter D. Spear
Joseph P. Hammang
E. Edward Baetge
William G. Tsiaras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech USA Inc
Original Assignee
Neurotech USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech USA Inc filed Critical Neurotech USA Inc
Publication of CA2264895A1 publication Critical patent/CA2264895A1/en
Application granted granted Critical
Publication of CA2264895C publication Critical patent/CA2264895C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002264895A 1996-03-22 1997-03-24 Device and method for treating ophthalmic diseases Expired - Fee Related CA2264895C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/620,982 US5904144A (en) 1996-03-22 1996-03-22 Method for treating ophthalmic diseases
US08/620,982 1996-03-22
PCT/US1997/004701 WO1997034586A2 (en) 1996-03-22 1997-03-24 Device and method for treating ophthalmic diseases

Publications (2)

Publication Number Publication Date
CA2264895A1 CA2264895A1 (en) 1997-09-25
CA2264895C true CA2264895C (en) 2008-05-27

Family

ID=24488233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264895A Expired - Fee Related CA2264895C (en) 1996-03-22 1997-03-24 Device and method for treating ophthalmic diseases

Country Status (10)

Country Link
US (1) US5904144A (enExample)
EP (2) EP0927024B8 (enExample)
JP (3) JP2000507854A (enExample)
AT (2) ATE296087T1 (enExample)
AU (1) AU716400B2 (enExample)
CA (1) CA2264895C (enExample)
DE (2) DE69739792D1 (enExample)
DK (2) DK1574209T3 (enExample)
ES (2) ES2342075T3 (enExample)
WO (1) WO1997034586A2 (enExample)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US6399058B1 (en) * 1997-09-17 2002-06-04 Alcon Manufacturing, Ltd. Methods for treating ocular diseases
US7282482B2 (en) * 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
JP2002534139A (ja) * 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
EP1179061B1 (en) * 1999-05-07 2006-09-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for treating tumors using antiangiogenic compounds
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
AU775149B2 (en) 1999-10-21 2004-07-22 Alcon Inc. Sub-tenon drug delivery
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
AU780634C (en) * 2000-02-11 2006-02-23 Genvec, Inc. Gene Therapy for treating ocular-related disorders
ATE547080T1 (de) * 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
US6697668B2 (en) * 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US6546284B2 (en) * 2001-01-25 2003-04-08 Iomed, Inc. Fluid retention assembly for an iontophoretic delivery device and associated method for preparing the same
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6875165B2 (en) * 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US7031776B2 (en) * 2001-06-29 2006-04-18 Optobionics Methods for improving damaged retinal cell function
US20050033202A1 (en) * 2001-06-29 2005-02-10 Chow Alan Y. Mechanically activated objects for treatment of degenerative retinal disease
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
PT1385452E (pt) * 2001-07-23 2006-12-29 Alcon Inc Dispositivo de administração de fármacos oftálmicos
DE60217679T2 (de) 2001-07-23 2007-10-25 Alcon Inc. Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
AU2002319282B2 (en) * 2001-08-01 2007-06-28 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
CA2689424A1 (en) * 2002-09-29 2004-04-08 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US8021680B2 (en) * 2003-05-02 2011-09-20 Surmodics, Inc. Controlled release bioactive agent delivery device
AU2004245175C1 (en) 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
WO2005009297A1 (en) * 2003-07-10 2005-02-03 Alcon, Inc. Ophthalmic drug delivery device
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
IL159818A0 (en) * 2004-01-12 2004-06-20 Nulens Ltd Intraocular structure
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
BRPI0507690A (pt) * 2004-02-12 2007-07-24 Neovista Inc métodos e aparelho para a braquiterapia intra-ocular
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
WO2006014484A2 (en) * 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
WO2006023130A2 (en) * 2004-08-12 2006-03-02 Surmodics, Inc. Biodegradable controlled release bioactive agent delivery device
US8246569B1 (en) 2004-08-17 2012-08-21 California Institute Of Technology Implantable intraocular pressure drain
WO2006041805A1 (en) * 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US20070077270A1 (en) * 2005-03-28 2007-04-05 Clemson University Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
US8088567B2 (en) 2005-04-01 2012-01-03 Nsgene A/S Human immortalised neural precursor cell line
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
WO2006122551A2 (en) 2005-05-17 2006-11-23 Nsgene A/S An implantable therapy system for treating a living being with an active factor
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
EP1951372A4 (en) 2005-11-15 2011-06-22 Neovista Inc METHOD AND DEVICE FOR INTRA-ECULAR BRACHYTHERAPY
EP1968594B1 (en) 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP1971288B1 (en) 2005-12-30 2013-02-13 Neurotech USA, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
CN101389295B (zh) * 2006-01-17 2010-11-10 纽镜有限公司 眼球内药物分配器
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
EP2316505B1 (en) 2006-03-14 2017-01-18 University Of Southern California Mems device for delivery of therapeutic agents
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CA2670944A1 (en) * 2006-12-18 2008-06-26 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
EP2242464B2 (en) 2007-12-20 2017-03-01 University Of Southern California Apparatus for delivering therapeutic agents
WO2009089094A2 (en) * 2008-01-03 2009-07-16 University Of Southern California Implantable drug-delivery devices, and apparatus and methods for refilling the devices
US9162024B2 (en) * 2008-05-08 2015-10-20 Minipumps, Llc Drug-delivery pumps and methods of manufacture
MX2010012212A (es) 2008-05-08 2011-09-27 Minipumps Llc Dispositivos implantables para suministro de fármacos, y áparato y métodos para llenar los dispositivos.
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
CN104353150A (zh) * 2008-05-08 2015-02-18 迷你泵有限责任公司 可植入泵和用于可植入泵的插管
AU2009256236A1 (en) 2008-06-04 2009-12-10 Neovista, Inc. Handheld radiation delivery system for advancing a radiation source wire
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
CA2750027C (en) 2009-01-23 2020-11-10 Nsgene A/S Improved cell lines and their use in encapsulated cell biodelivery
US8372036B2 (en) * 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
JP5758388B2 (ja) 2009-08-18 2015-08-05 ミニパンプス， エルエルシー 適応制御を有する電解質薬物送達ポンプ
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
WO2012041320A1 (en) 2010-09-27 2012-04-05 Nsgene A/S Implantable cell device with supportive and radial diffusive scaffolding
JP6149226B2 (ja) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013034157A1 (en) 2011-09-05 2013-03-14 Nsgene A/S Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
CA2856703A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
RU2494711C1 (ru) * 2012-05-18 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ хирургического лечения прогрессирующей и осложненной миопии
CA2874824C (en) 2012-06-01 2021-10-26 Surmodics, Inc. Apparatus and methods for coating balloon catheters
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
EP3043836B1 (en) * 2013-09-11 2023-05-10 Neurotech USA, Inc. Encapsulated cell therapy cartridge
EP3217924B1 (en) 2014-11-10 2025-07-16 ForSight Vision4, Inc. Expandable drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2021087476A1 (en) * 2019-11-01 2021-05-06 Neurotech Usa, Inc. System, apparatuses, devices, and methods for packaging an analyte diffusive implantable device
US12678440B2 (en) 2020-02-26 2026-07-14 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
US12496612B2 (en) 2021-01-08 2025-12-16 Surmodics, Inc. Coating application system and methods for coating rotatable medical devices

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116798A (ja) * 1974-08-01 1976-02-10 Mihairoichi Kurasunofu Mihairu Jinkosuishotai
US5266562A (en) * 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5279298A (en) * 1992-11-20 1994-01-18 The Johns Hopkins University Method and apparatus to identify and treat neovascular membranes in the eye
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication

Also Published As

Publication number Publication date
US5904144A (en) 1999-05-18
AU2541997A (en) 1997-10-10
DE69733357D1 (de) 2005-06-30
WO1997034586A2 (en) 1997-09-25
EP0927024A2 (en) 1999-07-07
DE69733357T2 (de) 2006-02-02
AU716400B2 (en) 2000-02-24
DE69739792D1 (de) 2010-04-15
DK1574209T3 (da) 2010-05-31
CA2264895A1 (en) 1997-09-25
EP0927024B8 (en) 2005-08-31
DK0927024T3 (da) 2005-08-29
ATE296087T1 (de) 2005-06-15
EP1574209B1 (en) 2010-03-03
WO1997034586A3 (en) 1997-10-23
EP0927024B1 (en) 2005-05-25
EP1574209A1 (en) 2005-09-14
JP4740077B2 (ja) 2011-08-03
JP2000507854A (ja) 2000-06-27
ES2242223T3 (es) 2005-11-01
JP2006342185A (ja) 2006-12-21
JP2010265314A (ja) 2010-11-25
ES2342075T3 (es) 2010-07-01
ATE459335T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
AU716400B2 (en) Device and method for treating ophthalmic diseases
US6436427B1 (en) Device and method for treating ophthalmic diseases
JP5247468B2 (ja) 生物活性分子の送達のための微粒子化デバイスおよびその使用方法
JP4954374B2 (ja) カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９
US20160120695A1 (en) Use of pedf in an encapsulated cell-based delivery system
EP3662923A1 (en) Use of encapsulated cell therapy for treatment of ophthalmic disorders
US20020076397A1 (en) Intraocular transplantation of encapsulated cells
AU708536B2 (en) System and method for delivery of cytokines using encapsulated cytokine-secreting cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150324